March 3, 2026Open Access

Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy

Key Points

Disease stability was observed following radiotherapy and camrelizumab treatment.
Patient had a MET exon 14 skipping mutation and high PD-L1 expression.
Combination therapy showed promise in treating lung adenocarcinoma with brain metastasis.
Findings support further evaluation of immunotherapy in larger lung cancer cohorts.

Abstract

The combination of brain radiotherapy and camrelizumab demonstrated efficacy in a lung adenocarcinoma patient with BM and METex14. These findings suggest that immunotherapy may represent a potential treatment approach for high PD-L1 expression of METex14 NSCLC patients, warranting further investigation in larger cohorts.

Bookmark

View Full Paper

Cite This Study

Ma et al. (Tue,) studied this question.

synapsesocial.com/papers/69a76063c6e9836116a2d176 https://doi.org/https://doi.org/10.3389/fimmu.2026.1719029

Bookmark

View Full Paper